Concepedia

Gren Z. Wang

GZ

Statistics

Publications

6

Citations

353

H-Index

6

Active since

2006

Affiliations

GlaxoSmithKline (United States)(Current)

Research Triangle Park Foundation

Gren Z. Wang is an author at GlaxoSmithKline (United States) specializing in pharmacology, drug discovery, and medicinal chemistry.

Publications per year

2006–2019

6

Publications

6

Development of Dihydropyridone Indazole Amides as Selective Rho-Kinase Inhibitors

Krista Goodman, Haifeng Cui, Sarah E. Dowdell et al. · Journal of Medicinal Chemistry · 2006 · 156 citations · Full text

, , +17

Potent, Selective and Orally Bioavailable Dihydropyrimidine Inhibitors of Rho Kinase (ROCK1) as Potential Therapeutic Agents for Cardiovascular Diseases

Clark A. Sehon, Gren Z. Wang, Andrew Q. Viet et al. · Journal of Medicinal Chemistry · 2008 · 72 citations · Full text

, , +13

Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[<i>d</i>]thiazol-5-ylamino)-6-(<i>tert</i>-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases

Pamela A. Haile, Linda Casillas, Bartholomew J. Votta et al. · Journal of Medicinal Chemistry · 2019 · 65 citations · Full text

, , +17

Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel

Pamela A. Haile, Linda Casillas, Michael J. Bury et al. · ACS Medicinal Chemistry Letters · 2018 · 36 citations · Full text

, , +14

Aminomethylpiperazines as selective urotensin antagonists

Mark A. Hilfiker, Daohua Zhang, Sarah E. Dowdell et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 13 citations · Full text

, , +4

1–5 of 6